InMode (NASDAQ:INMD – Free Report) had its price target raised by UBS Group from $24.00 to $26.00 in a report issued on Wednesday morning, Benzinga reports. They currently have a neutral rating on the healthcare company’s stock. Several other brokerages have also recently commented on INMD. Canaccord Genuity Group restated a hold rating and set […]